Pharma Execs: China Slowly Returning To Growth But Uncertainty Remains
MNC Q4 Highlights
Executive Summary
Just how dynamic is the China market for multinationals? AstraZeneca is seeing growth returning while Pfizer is finding it challenging to estimate Paxlovid demand, Sanofi is encouraged by volume gains and GSK is predicting a "sizeable" rebound. Top executives from Novartis and Roche also shed light on other challenges facing global pharma firms in the world's second-largest pharma market as they reported annual results.
You may also be interested in...
China Business Pessimism Grows Amid COVID Origin Assessment, Congressional Hearing
Simmering US-China tensions dash hopes that a recent border reopening will put many collaborations back on track, even as more than half foreign businesses now downgrade the importance of investing in China.
China Approves Two More Home-Grown COVID-19 Antivirals
Top-line results for two newly approved COVID-19 antivirals in China showed roughly 1.5- to two-day cuts in median time to symptom resolution or recovery in mild-to-moderate Omicron patients versus placebo.
China Suspends GSK Tender Qualification Under Dutasteride Ban
GSK becomes the second foreign pharma firm in recent months to be hit with a ban on the import, sale and use of a product by increasingly assertive Chinese regulatory authorities.